Otsuka Pharmaceutical Company, Limited

Taketoshi Izawa

Yoshimasa Nakano

Wasei Miyazaki

Masanao Shinohara

Hirotsugu Kaise

Yasuo Oshiro

Michiharu Sugawara

Setsuyoshi Uetsuki

Tomoyuki Kawaguchi

Akira Wada

A novel pyrazinoxide compound of NF-1616-904 having the formula (1), ##STR1## prepared by hydrolyzing the intermediate compound of NF-1616-902 which is separated from a culture broth of a microorganism belonging to the genus Thielavia. The pyazinoxide compound of NF-1616-904 possess biological and pharmacological activities, and is useful agent for preventing and treating diseases caused by superoxide radicals (O.sub.2.sup.-), and nephritis.

Novel pyrazinoxide compound of NF-1616-904 and a pharmaceutical

A prophylactic or therapeutic composition for hepatitis is disclosed comprising a prophylactically or therapeutically effective amount of a sesquiterpene compound represented by the formula (I) or (II) ##STR1## or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.

Composition for prophylaxis and therapy of hepatitis

A pharmaceutical composition having an anticomplementary activity comprising a therapeutically effective amount of at least one soyasapogenol B compound represented by the general formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom or a group represented by the formula: ##STR2## wherein R.sup.2 represents a hydrogen atom or a hydroxymethyl group, R.sup.3 represents a hydrogen atom or a rhamnopyranosyl group, and R.sup.4 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.

Anticomplementary agents comprising soyasapogenol B compounds

A sesquiterpene derivative expressed by the general formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a lower alkyl group or a lower alkanoyl group; R.sup.2 and R.sup.3, which may be the same or different, each represents a formyl group, a hydroxymethyl group, a hydroxyl group, a carboxyl group, a lower alkanoyloxymethyl group, or a group of the formula --CH.dbd.CR.sup.7 R.sup.8, wherein R.sup.7 and R.sup.8, which may be the same or different, each represents a hydrogen atom, a cyano group, a lower alkoxycarbonyl group or a carboxyl group, or R.sup.2 and R.sup.3 may combine to form a lactone ring of the formula ##STR2## in which R.sup.9 represents a hydrogen atom or a hydroxyl group; R.sup.4 and R.sup.6, which may be the same or different, each represents a hydroxyl group or a lower alkanoyloxy group; R.sup.5 represents a hydrogen atom; R.sup.4 and R.sup.5 may together form an oxo group (.dbd.O); and R.sup.4 and R.sup.6 may combine to form a lower alkylidenedioxy group, the pharmaceutically acceptable salts thereof, processes for the production of the compounds of the general formula (I) and the salts thereof, pharmaceutical composition containing the compounds of the general formula (I) and the salts thereof, and method of use of the compounds of the general formula (I) and the salts thereof.

Sesquiterpene derivatives having anti-complementary activity

3-0-(.beta.-D-Glucuronopyranosyl)-soyasapogenol B represented by the formula (I): ##STR1## and salts thereof and process for preparing the same are disclosed. The compound represented by the formula (I) and salts thereof have anticomplementary activity and are useful as therapeutic agents for autoimmune diseases, collagen diseases, and rheumatic diseases.

Growing community of inventors

Tokushima, Japan

Taketoshi Izawa